Shopping Cart 0
Cart Subtotal
USD 0

Generics Global Industry Almanac_2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 8985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Generics Global Industry Almanac_2017

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the global generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The market value is evaluated at ex-factory prices.

Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

All currency conversions were calculated at constant average annual 2015 exchange rates.

The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.

The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Scope

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global generics market

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market

Leading company profiles reveal details of key generics market players global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to buy

What was the size of the global generics market by value in 2016?

What will be the size of the global generics market in 2021?

What factors are affecting the strength of competition in the global generics market?

How has the market performed over the last five years?

Who are the top competitors in the global generics market?

READ MORE

Table Of Content

Scope

Table of Contents

EXECUTIVE SUMMARY

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

Global Generics

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Asia-Pacific

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Europe

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in France

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Germany

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Australia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Brazil

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in China

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in India

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Indonesia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Italy

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Japan

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Mexico

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The Netherlands

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in North America

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Russia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Scandinavia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Singapore

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in South Africa

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in South Korea

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Spain

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Turkey

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United Kingdom

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United States

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading companies

Appendix

Methodology

About MarketLine


List Of Figure

List of Figures

Figure 1: Global generics market value: $ billion, 2012-16

Figure 2: Global generics market volume: % of total pharma volume, 2012-16

Figure 3: Global generics market geography segmentation: % share, by value, 2016

Figure 4: Global generics market value forecast: $ billion, 2016-21

Figure 5: Global generics market volume forecast: % of total pharma volume, 2016-21

Figure 6: Forces driving competition in the global generics market, 2016

Figure 7: Drivers of buyer power in the global generics market, 2016

Figure 8: Drivers of supplier power in the global generics market, 2016

Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016

Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016

Figure 11: Drivers of degree of rivalry in the global generics market, 2016

Figure 12: Asia-Pacific generics market value: $ billion, 2012-16

Figure 13: Asia-Pacific generics market volume: % of total pharma volume, 2012-16

Figure 14: Asia-Pacific generics market geography segmentation: % share, by value, 2016

Figure 15: Asia-Pacific generics market value forecast: $ billion, 2016-21

Figure 16: Asia-Pacific generics market volume forecast: % of total pharma volume, 2016-21

Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016

Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016

Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016

Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016

Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016

Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016

Figure 23: Europe generics market value: $ billion, 2012-16

Figure 24: Europe generics market volume: % of total pharma volume, 2012-16

Figure 25: Europe generics market geography segmentation: % share, by value, 2016

Figure 26: Europe generics market value forecast: $ billion, 2016-21

Figure 27: Europe generics market volume forecast: % of total pharma volume, 2016-21

Figure 28: Forces driving competition in the generics market in Europe, 2016

Figure 29: Drivers of buyer power in the generics market in Europe, 2016

Figure 30: Drivers of supplier power in the generics market in Europe, 2016

Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016

Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016

Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016

Figure 34: France generics market value: $ billion, 2012-16

Figure 35: France generics market volume: % of total pharma volume, 2012-16

Figure 36: France generics market geography segmentation: % share, by value, 2016

Figure 37: France generics market value forecast: $ billion, 2016-21

Figure 38: France generics market volume forecast: % of total pharma volume, 2016-21

Figure 39: Forces driving competition in the generics market in France, 2016

Figure 40: Drivers of buyer power in the generics market in France, 2016

Figure 41: Drivers of supplier power in the generics market in France, 2016

Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016

Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016

Figure 44: Drivers of degree of rivalry in the generics market in France, 2016

Figure 45: Germany generics market value: $ billion, 2012-16

Figure 46: Germany generics market volume: % of total pharma volume, 2012-16

Figure 47: Germany generics market geography segmentation: % share, by value, 2016

Figure 48: Germany generics market value forecast: $ billion, 2016-21

Figure 49: Germany generics market volume forecast: % of total pharma volume, 2016-21

Figure 50: Forces driving competition in the generics market in Germany, 2016

Figure 51: Drivers of buyer power in the generics market in Germany, 2016

Figure 52: Drivers of supplier power in the generics market in Germany, 2016

Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016

Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016

Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016

Figure 56: Australia generics market value: $ billion, 2012-16

Figure 57: Australia generics market volume: % of total pharma volume, 2012-16

Figure 58: Australia generics market geography segmentation: % share, by value, 2016

Figure 59: Australia generics market value forecast: $ billion, 2016-21

Figure 60: Australia generics market volume forecast: % of total pharma volume, 2016-21

Figure 61: Forces driving competition in the generics market in Australia, 2016

Figure 62: Drivers of buyer power in the generics market in Australia, 2016

Figure 63: Drivers of supplier power in the generics market in Australia, 2016

Figure 64: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016

Figure 65: Factors influencing the threat of substitutes in the generics market in Australia, 2016

Figure 66: Drivers of degree of rivalry in the generics market in Australia, 2016

Figure 67: Brazil generics market value: $ billion, 2012-16

Figure 68: Brazil generics market volume: % of total pharma volume, 2012-16

Figure 69: Brazil generics market geography segmentation: % share, by value, 2016

Figure 70: Brazil generics market value forecast: $ billion, 2016-21

Figure 71: Brazil generics market volume forecast: % of total pharma volume, 2016-21

Figure 72: Forces driving competition in the generics market in Brazil, 2016

Figure 73: Drivers of buyer power in the generics market in Brazil, 2016

Figure 74: Drivers of supplier power in the generics market in Brazil, 2016

Figure 75: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016

Figure 76: Factors influencing the threat of substitutes in the generics market in Brazil, 2016

Figure 77: Drivers of degree of rivalry in the generics market in Brazil, 2016

Figure 78: Canada generics market value: $ billion, 2012-16

Figure 79: Canada generics market volume: % of total pharma volume, 2012-16

Figure 80: Canada generics market geography segmentation: % share, by value, 2016

Figure 81: Canada generics market value forecast: $ billion, 2016-21

Figure 82: Canada generics market volume forecast: % of total pharma volume, 2016-21

Figure 83: Forces driving competition in the generics market in Canada, 2016

Figure 84: Drivers of buyer power in the generics market in Canada, 2016

Figure 85: Drivers of supplier power in the generics market in Canada, 2016

Figure 86: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016

Figure 87: Factors influencing the threat of substitutes in the generics market in Canada, 2016

Figure 88: Drivers of degree of rivalry in the generics market in Canada, 2016

Figure 89: China generics market value: $ billion, 2012-16

Figure 90: China generics market volume: % of total pharma volume, 2012-16

Figure 91: China generics market geography segmentation: % share, by value, 2016

Figure 92: China generics market value forecast: $ billion, 2016-21

Figure 93: China generics market volume forecast: % of total pharma volume, 2016-21

Figure 94: Forces driving competition in the generics market in China, 2016

Figure 95: Drivers of buyer power in the generics market in China, 2016

Figure 96: Drivers of supplier power in the generics market in China, 2016

Figure 97: Factors influencing the likelihood of new entrants in the generics market in China, 2016

Figure 98: Factors influencing the threat of substitutes in the generics market in China, 2016

Figure 99: Drivers of degree of rivalry in the generics market in China, 2016

Figure 100: India generics market value: $ billion, 2012-16

Figure 101: India generics market volume: % of total pharma volume, 2012-16

Figure 102: India generics market geography segmentation: % share, by value, 2016

Figure 103: India generics market value forecast: $ billion, 2016-21

Figure 104: India generics market volume forecast: % of total pharma volume, 2016-21

Figure 105: Forces driving competition in the generics market in India, 2016

Figure 106: Drivers of buyer power in the generics market in India, 2016

Figure 107: Drivers of supplier power in the generics market in India, 2016

Figure 108: Factors influencing the likelihood of new entrants in the generics market in India, 2016

Figure 109: Factors influencing the threat of substitutes in the generics market in India, 2016

Figure 110: Drivers of degree of rivalry in the generics market in India, 2016

Figure 111: Indonesia generics market value: $ billion, 2012-16

Figure 112: Indonesia generics market volume: % of total pharma volume, 2012-16

Figure 113: Indonesia generics market geography segmentation: % share, by value, 2016

Figure 114: Indonesia generics market value forecast: $ billion, 2016-21

Figure 115: Indonesia generics market volume forecast: % of total pharma volume, 2016-21

Figure 116: Forces driving competition in the generics market in Indonesia, 2016

Figure 117: Drivers of buyer power in the generics market in Indonesia, 2016

Figure 118: Drivers of supplier power in the generics market in Indonesia, 2016

Figure 119: Factors influencing the likelihood of new entrants in the generics market in Indonesia, 2016

Figure 120: Factors influencing the threat of substitutes in the generics market in Indonesia, 2016

Figure 121: Drivers of degree of rivalry in the generics market in Indonesia, 2016

Figure 122: Italy generics market value: $ billion, 2012-16

Figure 123: Italy generics market volume: % of total pharma volume, 2012-16

Figure 124: Italy generics market geography segmentation: % share, by value, 2016

Figure 125: Italy generics market value forecast: $ billion, 2016-21

Figure 126: Italy generics market volume forecast: % of total pharma volume, 2016-21

Figure 127: Forces driving competition in the generics market in Italy, 2016

Figure 128: Drivers of buyer power in the generics market in Italy, 2016

Figure 129: Drivers of supplier power in the generics market in Italy, 2016

Figure 130: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016

Figure 131: Factors influencing the threat of substitutes in the generics market in Italy, 2016

Figure 132: Drivers of degree of rivalry in the generics market in Italy, 2016

Figure 133: Japan generics market value: $ billion, 2012-16

Figure 134: Japan generics market volume: % of total pharma volume, 2012-16

Figure 135: Japan generics market geography segmentation: % share, by value, 2016

Figure 136: Japan generics market value forecast: $ billion, 2016-21

Figure 137: Japan generics market volume forecast: % of total pharma volume, 2016-21

Figure 138: Forces driving competition in the generics market in Japan, 2016

Figure 139: Drivers of buyer power in the generics market in Japan, 2016

Figure 140: Drivers of supplier power in the generics market in Japan, 2016

Figure 141: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016

Figure 142: Factors influencing the threat of substitutes in the generics market in Japan, 2016

Figure 143: Drivers of degree of rivalry in the generics market in Japan, 2016

Figure 144: Mexico generics market value: $ billion, 2012-16

Figure 145: Mexico generics market volume: % of total pharma volume, 2012-16

Figure 146: Mexico generics market geography segmentation: % share, by value, 2016

Figure 147: Mexico generics market value forecast: $ billion, 2016-21

Figure 148: Mexico generics market volume forecast: % of total pharma volume, 2016-21

Figure 149: Forces driving competition in the generics market in Mexico, 2016

Figure 150: Drivers of buyer power in the generics market in Mexico, 2016

Figure 151: Drivers of supplier power in the generics market in Mexico, 2016

Figure 152: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016

Figure 153: Factors influencing the threat of substitutes in the generics market in Mexico, 2016

Figure 154: Drivers of degree of rivalry in the generics market in Mexico, 2016

Figure 155: Netherlands generics market value: $ billion, 2012-16

Figure 156: Netherlands generics market volume: % of total pharma volume, 2012-16

Figure 157: Netherlands generics market geography segmentation: % share, by value, 2016

Figure 158: Netherlands generics market value forecast: $ billion, 2016-21

Figure 159: Netherlands generics market volume forecast: % of total pharma volume, 2016-21

Figure 160: Forces driving competition in the generics market in the Netherlands, 2016

Figure 161: Drivers of buyer power in the generics market in the Netherlands, 2016

Figure 162: Drivers of supplier power in the generics market in the Netherlands, 2016

Figure 163: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016

Figure 164: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016

Figure 165: Drivers of degree of rivalry in the generics market in the Netherlands, 2016

Figure 166: North America generics market value: $ billion, 2012-16

Figure 167: North America generics market volume: % of total pharma volume, 2012-16

Figure 168: North America generics market geography segmentation: % share, by value, 2016

Figure 169: North America generics market value forecast: $ billion, 2016-21

Figure 170: North America generics market volume forecast: % of total pharma volume, 2016-21

Figure 171: Forces driving competition in the generics market in North America, 2016

Figure 172: Drivers of buyer power in the generics market in North America, 2016

Figure 173: Drivers of supplier power in the generics market in North America, 2016

Figure 174: Factors influencing the likelihood of new entrants in the generics market in North America, 2016

Figure 175: Factors influencing the threat of substitutes in the generics market in North America, 2016

Figure 176: Drivers of degree of rivalry in the generics market in North America, 2016

Figure 177: Russia generics market value: $ billion, 2012-16

Figure 178: Russia generics market volume: % of total pharma volume, 2012-16

Figure 179: Russia generics market geography segmentation: % share, by value, 2016

Figure 180: Russia generics market value forecast: $ billion, 2016-21

Figure 181: Russia generics market volume forecast: % of total pharma volume, 2016-21

Figure 182: Forces driving competition in the generics market in Russia, 2016

Figure 183: Drivers of buyer power in the generics market in Russia, 2016

Figure 184: Drivers of supplier power in the generics market in Russia, 2016

Figure 185: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016

Figure 186: Factors influencing the threat of substitutes in the generics market in Russia, 2016

Figure 187: Drivers of degree of rivalry in the generics market in Russia, 2016

Figure 188: Scandinavia generics market value: $ billion, 2012-16

Figure 189: Scandinavia generics market volume: % of total pharma volume, 2012-16

Figure 190: Scandinavia generics market geography segmentation: % share, by value, 2016

Figure 191: Scandinavia generics market value forecast: $ billion, 2016-21

Figure 192: Scandinavia generics market volume forecast: % of total pharma volume, 2016-21

Figure 193: Forces driving competition in the generics market in Scandinavia, 2016

Figure 194: Drivers of buyer power in the generics market in Scandinavia, 2016

Figure 195: Drivers of supplier power in the generics market in Scandinavia, 2016

Figure 196: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2016

Figure 197: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2016

Figure 198: Drivers of degree of rivalry in the generics market in Scandinavia, 2016

Figure 199: Singapore generics market value: $ billion, 2012-16

Figure 200: Singapore generics market volume: % of total pharma volume, 2012-16

Figure 201: Singapore generics market geography segmentation: % share, by value, 2016

Figure 202: Singapore generics market value forecast: $ billion, 2016-21

Figure 203: Singapore generics market volume forecast: % of total pharma volume, 2016-21

Figure 204: Forces driving competition in the generics market in Singapore, 2016

Figure 205: Drivers of buyer power in the generics market in Singapore, 2016

Figure 206: Drivers of supplier power in the generics market in Singapore, 2016

Figure 207: Factors influencing the likelihood of new entrants in the generics market in Singapore, 2016

Figure 208: Factors influencing the threat of substitutes in the generics market in Singapore, 2016

Figure 209: Drivers of degree of rivalry in the generics market in Singapore, 2016

Figure 210: South Africa generics market value: $ billion, 2012-16

Figure 211: South Africa generics market volume: % of total pharma volume, 2012-16

Figure 212: South Africa generics market geography segmentation: % share, by value, 2016

Figure 213: South Africa generics market value forecast: $ billion, 2016-21

Figure 214: South Africa generics market volume forecast: % of total pharma volume, 2016-21

Figure 215: Forces driving competition in the generics market in South Africa, 2016

Figure 216: Drivers of buyer power in the generics market in South Africa, 2016

Figure 217: Drivers of supplier power in the generics market in South Africa, 2016

Figure 218: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2016

Figure 219: Factors influencing the threat of substitutes in the generics market in South Africa, 2016

Figure 220: Drivers of degree of rivalry in the generics market in South Africa, 2016

Figure 221: South Korea generics market value: $ billion, 2012-16

Figure 222: South Korea generics market volume: % of total pharma volume, 2012-16

Figure 223: South Korea generics market geography segmentation: % share, by value, 2016

Figure 224: South Korea generics market value forecast: $ billion, 2016-21

Figure 225: South Korea generics market volume forecast: % of total pharma volume, 2016-21

Figure 226: Forces driving competition in the generics market in South Korea, 2016

Figure 227: Drivers of buyer power in the generics market in South Korea, 2016

Figure 228: Drivers of supplier power in the generics market in South Korea, 2016

Figure 229: Factors influencing the likelihood of new entrants in the generics market in South Korea, 2016

Figure 230: Factors influencing the threat of substitutes in the generics market in South Korea, 2016

Figure 231: Drivers of degree of rivalry in the generics market in South Korea, 2016

Figure 232: Spain generics market value: $ billion, 2012-16

Figure 233: Spain generics market volume: % of total pharma volume, 2012-16

Figure 234: Spain generics market geography segmentation: % share, by value, 2016

Figure 235: Spain generics market value forecast: $ billion, 2016-21

Figure 236: Spain generics market volume forecast: % of total pharma volume, 2016-21

Figure 237: Forces driving competition in the generics market in Spain, 2016

Figure 238: Drivers of buyer power in the generics market in Spain, 2016

Figure 239: Drivers of supplier power in the generics market in Spain, 2016

Figure 240: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016

Figure 241: Factors influencing the threat of substitutes in the generics market in Spain, 2016

Figure 242: Drivers of degree of rivalry in the generics market in Spain, 2016

Figure 243: Turkey generics market value: $ billion, 2012-16

Figure 244: Turkey generics market volume: % of total pharma volume, 2012-16

Figure 245: Turkey generics market geography segmentation: % share, by value, 2016

Figure 246: Turkey generics market value forecast: $ billion, 2016-21

Figure 247: Turkey generics market volume forecast: % of total pharma volume, 2016-21

Figure 248: Forces driving competition in the generics market in Turkey, 2016

Figure 249: Drivers of buyer power in the generics market in Turkey, 2016

Figure 250: Drivers of supplier power in the generics market in Turkey, 2016

Figure 251: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2016

Figure 252: Factors influencing the threat of substitutes in the generics market in Turkey, 2016

Figure 253: Drivers of degree of rivalry in the generics market in Turkey, 2016

Figure 254: United Kingdom generics market value: $ billion, 2012-16

Figure 255: United Kingdom generics market volume: % of total pharma volume, 2012-16

Figure 256: United Kingdom generics market geography segmentation: % share, by value, 2016

Figure 257: United Kingdom generics market value forecast: $ billion, 2016-21

Figure 258: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21

Figure 259: Forces driving competition in the generics market in the United Kingdom, 2016

Figure 260: Drivers of buyer power in the generics market in the United Kingdom, 2016

Figure 261: Drivers of supplier power in the generics market in the United Kingdom, 2016

Figure 262: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016

Figure 263: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016

Figure 264: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016

Figure 265: United States generics market value: $ billion, 2012-16

Figure 266: United States generics market volume: % of total pharma volume, 2012-16

Figure 267: United States generics market geography segmentation: % share, by value, 2016

Figure 268: United States generics market value forecast: $ billion, 2016-21

Figure 269: United States generics market volume forecast: % of total pharma volume, 2016-21

Figure 270: Forces driving competition in the generics market in the United States, 2016

Figure 271: Drivers of buyer power in the generics market in the United States, 2016

Figure 272: Drivers of supplier power in the generics market in the United States, 2016

Figure 273: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016

Figure 274: Factors influencing the threat of substitutes in the generics market in the United States, 2016

Figure 275: Drivers of degree of rivalry in the generics market in the United States, 2016

Figure 276: Allergan plc: revenues & profitability

Figure 277: Allergan plc: assets & liabilities

Figure 278: Mylan Inc.: revenues & profitability

Figure 279: Mylan Inc.: assets & liabilities

Figure 280: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 281: Teva Pharmaceutical Industries Limited: assets & liabilities

Figure 282: Sun Pharmaceutical Industries Ltd.: revenues & profitability

Figure 283: Sun Pharmaceutical Industries Ltd.: assets & liabilities

Figure 284: Sanofi SA: revenues & profitability

Figure 285: Sanofi SA: assets & liabilities

Figure 286: STADA Arzneimittel AG: revenues & profitability

Figure 287: STADA Arzneimittel AG: assets & liabilities

Figure 288: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 289: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 290: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 291: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 292: Aurobindo Pharma Limited: revenues & profitability

Figure 293: Aurobindo Pharma Limited: assets & liabilities

Figure 294: Cipla Limited: revenues & profitability

Figure 295: Cipla Limited: assets & liabilities

Figure 296: Lupin Limited: revenues & profitability

Figure 297: Lupin Limited: assets & liabilities

Figure 298: PT Kalbe Farma Tbk: revenues & profitability

Figure 299: PT Kalbe Farma Tbk: assets & liabilities

Figure 300: PT Indofarma (Persero), Tbk: revenues & profitability

Figure 301: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 302: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 303: Sawai Pharmaceutical Co., Ltd.: revenues & profitability

Figure 304: Sawai Pharmaceutical Co., Ltd.: assets & liabilities

Figure 305: Abbott Laboratories: revenues & profitability

Figure 306: Abbott Laboratories: assets & liabilities

Figure 307: Krka, d. d., Novo mesto: revenues & profitability

Figure 308: Krka, d. d., Novo mesto: assets & liabilities

Figure 309: Adcock Ingram Holdings Limited: revenues & profitability

Figure 310: Adcock Ingram Holdings Limited: assets & liabilities

Figure 311: Yuhan Corporation: revenues & profitability

Figure 312: Yuhan Corporation: assets & liabilities

Figure 313: DEVA Holding: revenues & profitability

Figure 314: DEVA Holding: assets & liabilities


List Of Table

List of Tables

Table 1: Global generics market value: $ billion, 2012-16

Table 2: Global generics market volume: % of total pharma volume, 2012-16

Table 3: Global generics market geography segmentation: $ billion, 2016

Table 4: Global generics market value forecast: $ billion, 2016-21

Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21

Table 6: Asia-Pacific generics market value: $ billion, 2012-16

Table 7: Asia-Pacific generics market volume: % of total pharma volume, 2012-16

Table 8: Asia-Pacific generics market geography segmentation: $ billion, 2016

Table 9: Asia-Pacific generics market value forecast: $ billion, 2016-21

Table 10: Asia-Pacific generics market volume forecast: % of total pharma volume, 2016-21

Table 11: Europe generics market value: $ billion, 2012-16

Table 12: Europe generics market volume: % of total pharma volume, 2012-16

Table 13: Europe generics market geography segmentation: $ billion, 2016

Table 14: Europe generics market value forecast: $ billion, 2016-21

Table 15: Europe generics market volume forecast: % of total pharma volume, 2016-21

Table 16: France generics market value: $ billion, 2012-16

Table 17: France generics market volume: % of total pharma volume, 2012-16

Table 18: France generics market geography segmentation: $ billion, 2016

Table 19: France generics market value forecast: $ billion, 2016-21

Table 20: France generics market volume forecast: % of total pharma volume, 2016-21

Table 21: France size of population (million), 2012-16

Table 22: France gdp (constant 2005 prices, $ billion), 2012-16

Table 23: France gdp (current prices, $ billion), 2012-16

Table 24: France inflation, 2012-16

Table 25: France consumer price index (absolute), 2012-16

Table 26: France exchange rate, 2012-16

Table 27: Germany generics market value: $ billion, 2012-16

Table 28: Germany generics market volume: % of total pharma volume, 2012-16

Table 29: Germany generics market geography segmentation: $ billion, 2016

Table 30: Germany generics market value forecast: $ billion, 2016-21

Table 31: Germany generics market volume forecast: % of total pharma volume, 2016-21

Table 32: Germany size of population (million), 2012-16

Table 33: Germany gdp (constant 2005 prices, $ billion), 2012-16

Table 34: Germany gdp (current prices, $ billion), 2012-16

Table 35: Germany inflation, 2012-16

Table 36: Germany consumer price index (absolute), 2012-16

Table 37: Germany exchange rate, 2012-16

Table 38: Australia generics market value: $ billion, 2012-16

Table 39: Australia generics market volume: % of total pharma volume, 2012-16

Table 40: Australia generics market geography segmentation: $ billion, 2016

Table 41: Australia generics market value forecast: $ billion, 2016-21

Table 42: Australia generics market volume forecast: % of total pharma volume, 2016-21

Table 43: Australia size of population (million), 2012-16

Table 44: Australia gdp (constant 2005 prices, $ billion), 2012-16

Table 45: Australia gdp (current prices, $ billion), 2012-16

Table 46: Australia inflation, 2012-16

Table 47: Australia consumer price index (absolute), 2012-16

Table 48: Australia exchange rate, 2012-16

Table 49: Brazil generics market value: $ billion, 2012-16

Table 50: Brazil generics market volume: % of total pharma volume, 2012-16

Table 51: Brazil generics market geography segmentation: $ billion, 2016

Table 52: Brazil generics market value forecast: $ billion, 2016-21

Table 53: Brazil generics market volume forecast: % of total pharma volume, 2016-21

Table 54: Brazil size of population (million), 2012-16

Table 55: Brazil gdp (constant 2005 prices, $ billion), 2012-16

Table 56: Brazil gdp (current prices, $ billion), 2012-16

Table 57: Brazil inflation, 2012-16

Table 58: Brazil consumer price index (absolute), 2012-16

Table 59: Brazil exchange rate, 2012-16

Table 60: Canada generics market value: $ billion, 2012-16

Table 61: Canada generics market volume: % of total pharma volume, 2012-16

Table 62: Canada generics market geography segmentation: $ billion, 2016

Table 63: Canada generics market value forecast: $ billion, 2016-21

Table 64: Canada generics market volume forecast: % of total pharma volume, 2016-21

Table 65: Canada size of population (million), 2012-16

Table 66: Canada gdp (constant 2005 prices, $ billion), 2012-16

Table 67: Canada gdp (current prices, $ billion), 2012-16

Table 68: Canada inflation, 2012-16

Table 69: Canada consumer price index (absolute), 2012-16

Table 70: Canada exchange rate, 2012-16

Table 71: China generics market value: $ billion, 2012-16

Table 72: China generics market volume: % of total pharma volume, 2012-16

Table 73: China generics market geography segmentation: $ billion, 2016

Table 74: China generics market value forecast: $ billion, 2016-21

Table 75: China generics market volume forecast: % of total pharma volume, 2016-21

Table 76: China size of population (million), 2012-16

Table 77: China gdp (constant 2005 prices, $ billion), 2012-16

Table 78: China gdp (current prices, $ billion), 2012-16

Table 79: China inflation, 2012-16

Table 80: China consumer price index (absolute), 2012-16

Table 81: China exchange rate, 2012-16

Table 82: India generics market value: $ billion, 2012-16

Table 83: India generics market volume: % of total pharma volume, 2012-16

Table 84: India generics market geography segmentation: $ billion, 2016

Table 85: India generics market value forecast: $ billion, 2016-21

Table 86: India generics market volume forecast: % of total pharma volume, 2016-21

Table 87: India size of population (million), 2012-16

Table 88: India gdp (constant 2005 prices, $ billion), 2012-16

Table 89: India gdp (current prices, $ billion), 2012-16

Table 90: India inflation, 2012-16

Table 91: India consumer price index (absolute), 2012-16

Table 92: India exchange rate, 2012-16

Table 93: Indonesia generics market value: $ billion, 2012-16

Table 94: Indonesia generics market volume: % of total pharma volume, 2012-16

Table 95: Indonesia generics market geography segmentation: $ billion, 2016

Table 96: Indonesia generics market value forecast: $ billion, 2016-21

Table 97: Indonesia generics market volume forecast: % of total pharma volume, 2016-21

Table 98: Indonesia size of population (million), 2012-16

Table 99: Indonesia gdp (constant 2005 prices, $ billion), 2012-16

Table 100: Indonesia gdp (current prices, $ billion), 2012-16

Table 101: Indonesia inflation, 2012-16

Table 102: Indonesia consumer price index (absolute), 2012-16

Table 103: Indonesia exchange rate, 2012-16

Table 104: Italy generics market value: $ billion, 2012-16

Table 105: Italy generics market volume: % of total pharma volume, 2012-16

Table 106: Italy generics market geography segmentation: $ billion, 2016

Table 107: Italy generics market value forecast: $ billion, 2016-21

Table 108: Italy generics market volume forecast: % of total pharma volume, 2016-21

Table 109: Italy size of population (million), 2012-16

Table 110: Italy gdp (constant 2005 prices, $ billion), 2012-16

Table 111: Italy gdp (current prices, $ billion), 2012-16

Table 112: Italy inflation, 2012-16

Table 113: Italy consumer price index (absolute), 2012-16

Table 114: Italy exchange rate, 2012-16

Table 115: Japan generics market value: $ billion, 2012-16

Table 116: Japan generics market volume: % of total pharma volume, 2012-16

Table 117: Japan generics market geography segmentation: $ billion, 2016

Table 118: Japan generics market value forecast: $ billion, 2016-21

Table 119: Japan generics market volume forecast: % of total pharma volume, 2016-21

Table 120: Japan size of population (million), 2012-16

Table 121: Japan gdp (constant 2005 prices, $ billion), 2012-16

Table 122: Japan gdp (current prices, $ billion), 2012-16

Table 123: Japan inflation, 2012-16

Table 124: Japan consumer price index (absolute), 2012-16

Table 125: Japan exchange rate, 2012-16

Table 126: Mexico generics market value: $ billion, 2012-16

Table 127: Mexico generics market volume: % of total pharma volume, 2012-16

Table 128: Mexico generics market geography segmentation: $ billion, 2016

Table 129: Mexico generics market value forecast: $ billion, 2016-21

Table 130: Mexico generics market volume forecast: % of total pharma volume, 2016-21

Table 131: Mexico size of population (million), 2012-16

Table 132: Mexico gdp (constant 2005 prices, $ billion), 2012-16

Table 133: Mexico gdp (current prices, $ billion), 2012-16

Table 134: Mexico inflation, 2012-16

Table 135: Mexico consumer price index (absolute), 2012-16

Table 136: Mexico exchange rate, 2012-16

Table 137: Netherlands generics market value: $ billion, 2012-16

Table 138: Netherlands generics market volume: % of total pharma volume, 2012-16

Table 139: Netherlands generics market geography segmentation: $ billion, 2016

Table 140: Netherlands generics market value forecast: $ billion, 2016-21

Table 141: Netherlands generics market volume forecast: % of total pharma volume, 2016-21

Table 142: Netherlands size of population (million), 2012-16

Table 143: Netherlands gdp (constant 2005 prices, $ billion), 2012-16

Table 144: Netherlands gdp (current prices, $ billion), 2012-16

Table 145: Netherlands inflation, 2012-16

Table 146: Netherlands consumer price index (absolute), 2012-16

Table 147: Netherlands exchange rate, 2012-16

Table 148: North America generics market value: $ billion, 2012-16

Table 149: North America generics market volume: % of total pharma volume, 2012-16

Table 150: North America generics market geography segmentation: $ billion, 2016

Table 151: North America generics market value forecast: $ billion, 2016-21

Table 152: North America generics market volume forecast: % of total pharma volume, 2016-21

Table 153: Russia generics market value: $ billion, 2012-16

Table 154: Russia generics market volume: % of total pharma volume, 2012-16

Table 155: Russia generics market geography segmentation: $ billion, 2016

Table 156: Russia generics market value forecast: $ billion, 2016-21

Table 157: Russia generics market volume forecast: % of total pharma volume, 2016-21

Table 158: Russia size of population (million), 2012-16

Table 159: Russia gdp (constant 2005 prices, $ billion), 2012-16

Table 160: Russia gdp (current prices, $ billion), 2012-16

Table 161: Russia inflation, 2012-16

Table 162: Russia consumer price index (absolute), 2012-16

Table 163: Russia exchange rate, 2012-16

Table 164: Scandinavia generics market value: $ billion, 2012-16

Table 165: Scandinavia generics market volume: % of total pharma volume, 2012-16

Table 166: Scandinavia generics market geography segmentation: $ billion, 2016

Table 167: Scandinavia generics market value forecast: $ billion, 2016-21

Table 168: Scandinavia generics market volume forecast: % of total pharma volume, 2016-21

Table 169: Singapore generics market value: $ billion, 2012-16

Table 170: Singapore generics market volume: % of total pharma volume, 2012-16

Table 171: Singapore generics market geography segmentation: $ billion, 2016

Table 172: Singapore generics market value forecast: $ billion, 2016-21

Table 173: Singapore generics market volume forecast: % of total pharma volume, 2016-21

Table 174: Singapore size of population (million), 2012-16

Table 175: Singapore gdp (constant 2005 prices, $ billion), 2012-16

Table 176: Singapore gdp (current prices, $ billion), 2012-16

Table 177: Singapore inflation, 2012-16

Table 178: Singapore consumer price index (absolute), 2012-16

Table 179: Singapore exchange rate, 2012-16

Table 180: South Africa generics market value: $ billion, 2012-16

Table 181: South Africa generics market volume: % of total pharma volume, 2012-16

Table 182: South Africa generics market geography segmentation: $ billion, 2016

Table 183: South Africa generics market value forecast: $ billion, 2016-21

Table 184: South Africa generics market volume forecast: % of total pharma volume, 2016-21

Table 185: South Africa size of population (million), 2012-16

Table 186: South Africa gdp (constant 2005 prices, $ billion), 2012-16

Table 187: South Africa gdp (current prices, $ billion), 2012-16

Table 188: South Africa inflation, 2012-16

Table 189: South Africa consumer price index (absolute), 2012-16

Table 190: South Africa exchange rate, 2012-16

Table 191: South Korea generics market value: $ billion, 2012-16

Table 192: South Korea generics market volume: % of total pharma volume, 2012-16

Table 193: South Korea generics market geography segmentation: $ billion, 2016

Table 194: South Korea generics market value forecast: $ billion, 2016-21

Table 195: South Korea generics market volume forecast: % of total pharma volume, 2016-21

Table 196: South Korea size of population (million), 2012-16

Table 197: South Korea gdp (constant 2005 prices, $ billion), 2012-16

Table 198: South Korea gdp (current prices, $ billion), 2012-16

Table 199: South Korea inflation, 2012-16

Table 200: South Korea consumer price index (absolute), 2012-16

Table 201: South Korea exchange rate, 2012-16

Table 202: Spain generics market value: $ billion, 2012-16

Table 203: Spain generics market volume: % of total pharma volume, 2012-16

Table 204: Spain generics market geography segmentation: $ billion, 2016

Table 205: Spain generics market value forecast: $ billion, 2016-21

Table 206: Spain generics market volume forecast: % of total pharma volume, 2016-21

Table 207: Spain size of population (million), 2012-16

Table 208: Spain gdp (constant 2005 prices, $ billion), 2012-16

Table 209: Spain gdp (current prices, $ billion), 2012-16

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com